At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
In Brief
A Phase 4 clinical trial evaluating Olanzapine, Standard behavioral weight intervention, and 1 other intervention for Bipolar I Disorder and Schizophrenia. Completed, enrolled 203 participants across 14 sites in 4 countries.
Detailed Summary
Open-label safety study of oral olanzapine treatment in adolescents, aged 13 to 17 years, with bipolar I disorder (manic or mixed episodes) or schizophrenia.
Study Details
Timeline
Interventions
2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.